“Lupin US generics demand”

Pharma major Lupin Limited reported a stellar performance in its Q3FY26 results, with net profit surging 37.4% year-on-year to Rs 1,215 crore, driven by robust demand in the United States and emerging markets. The company’s revenue growth was supported by strong generics sales, new product launches, and improved operational efficiency. Key Highlights of Q3FY26 Drivers…